Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Analysis of the efficacy of a carfilzomib-based regimen in the treatment of relapsed and refractory multiple myeloma.

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJinfeng ZhouWCWeiyan ChenYLYu‐Chuan Li

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals a 53.8% response rate and significant differences in progression-free survival for patients, highlighting treatment options.

Key Points

  • Carfilzomib-based regimens show a 53.8% overall response rate in treating RRMM, indicating effective intervention.
  • Patients without plasmacytoma recurrence had a median progression-free survival of 12.3 months, contrasting with 6.2 months in those with recurrence.
  • This retrospective analysis involved 26 patients treated over a period from July 2021 to May 2024 at a single hospital, ensuring focused results.
  • Efficacy appears largely stable regardless of age or previous treatment lines, suggesting carfilzomib is a viable option across demographics.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/68c23c20b210217d64787d7chttps://doi.org/10.3760/cma.j.cn112138-20250313-00147
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study2025
  2. 2Comparative analysis of once-weekly versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma: a meta-analysis2025
  3. 3Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study.2025
  4. 4BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  5. 5Carfilzomib Augmented with high-dose melphalan conditioning regimen Enhances Response in patients with multiple myeloma eligible for ASCT：an investigator-initiated, prospective, multicenter study2025